Tofacitnib for the Treatment of Alopecia Areata and Variants
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus
kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia
areata and its variants.